Law Firm Kirby McInerney LLP Investigating Potential Claims On Behalf Of DUSA Pharmaceuticals, Inc. Shareholders

Kirby McInerney LLP is investigating potential claims against the Board of Directors of DUSA Pharmaceuticals, Inc. (“DUSA” or the “Company”) (NASDAQ: DUSA) related to the proposed acquisition of the Company by Sun Pharmaceutical Industries Limited. Under the terms of the agreement, Sun Pharmaceutical will commence a tender offer to acquire all of the outstanding common stock of DUSA for $8.00 per share in cash, or approximately $230 million.

The investigation concerns whether the DUSA Board of Directors violated its fiduciary duties by agreeing to this transaction and whether the proposed $8.00 per share consideration adequately values DUSA common shares. The average analyst price target for the Company’s shares is $8.33 per share, and at least one analyst has set a price target of $9.50 per share – 17% above the proposed acquisition price.

If you are a DUSA shareholder and wish to obtain additional information, please contact J. Brandon Walker, Esq. by email at bwalker@kmllp.com, or by telephone at (212) 699-1145 or (888) 529-4787.

Kirby McInerney LLP is a New York-based law firm concentrating in securities, shareholder, whistleblower, antitrust and consumer litigation. For additional information, please go to www.kmslaw.com.

Copyright Business Wire 2010

If you liked this article you might like

5 Stocks Under $10 Soaring Higher

DUSA's CEO Discusses Q2 2012 Results - Earnings Call Transcript

8 Stocks Under $10 Ripping Higher

DUSA Pharmaceuticals Inc. Stock Upgraded (DUSA)

DUSA Pharmaceuticals Inc. Stock Upgraded (DUSA)

DUSA Pharmaceuticals Inc. Stock Downgraded (DUSA)

DUSA Pharmaceuticals Inc. Stock Downgraded (DUSA)